Skip to content

EBIT at other companies

Arcus Biosciences logo
Arcus BiosciencesRCUS
-$134M-9.8%
Erasca, Inc. logo
Erasca, Inc.ERAS
-$187.91M-427%
Immunome logo
ImmunomeIMNM
-$59.33M-32.9%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-$78.59M+7.4%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Amgen logo
AmgenAMGN

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.36B+104%
Enterprise value$3.23B+110%
P/S14.5×+9.9×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Calculated from IDEAYA Biosciences, Inc.’s reported figures.

The official record: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about IDEAYA Biosciences, Inc.'s ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IDEAYA Biosciences, Inc.'s EBIT?
IDEAYA Biosciences, Inc. (IDYA) reported EBIT of -$108.54M in Q1 2026.
How has IDEAYA Biosciences, Inc.'s EBIT changed year-over-year?
IDEAYA Biosciences, Inc.'s EBIT decreased by 28.6% year-over-year, from -$84.39M to -$108.54M.
What is the long-term trend for IDEAYA Biosciences, Inc.'s EBIT?
Over 4 years (2021 to 2025), IDEAYA Biosciences, Inc.'s EBIT has grown at a 33.4% compound annual growth rate (CAGR), from -$50.27M to -$159.31M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.